236 related articles for article (PubMed ID: 26277104)
1. Synovial sarcoma is a gateway to the role of chromatin remodeling in cancer.
Zöllner SK; Rössig C; Toretsky JA
Cancer Metastasis Rev; 2015 Sep; 34(3):417-28. PubMed ID: 26277104
[TBL] [Abstract][Full Text] [Related]
2. Synovial Sarcoma: A Complex Disease with Multifaceted Signaling and Epigenetic Landscapes.
El Beaino M; Rassy E; Hadid B; Araujo DM; Pavlidis N; Lin PP
Curr Oncol Rep; 2020 Oct; 22(12):124. PubMed ID: 33025259
[TBL] [Abstract][Full Text] [Related]
3. SS18-SSX, the Oncogenic Fusion Protein in Synovial Sarcoma, Is a Cellular Context-Dependent Epigenetic Modifier.
Tamaki S; Fukuta M; Sekiguchi K; Jin Y; Nagata S; Hayakawa K; Hineno S; Okamoto T; Watanabe M; Woltjen K; Ikeya M; Kato T; Toguchida J
PLoS One; 2015; 10(11):e0142991. PubMed ID: 26571495
[TBL] [Abstract][Full Text] [Related]
4. SS18-SSX fusion protein-induced Wnt/β-catenin signaling is a therapeutic target in synovial sarcoma.
Trautmann M; Sievers E; Aretz S; Kindler D; Michels S; Friedrichs N; Renner M; Kirfel J; Steiner S; Huss S; Koch A; Penzel R; Larsson O; Kawai A; Tanaka S; Sonobe H; Waha A; Schirmacher P; Mechtersheimer G; Wardelmann E; Büttner R; Hartmann W
Oncogene; 2014 Oct; 33(42):5006-16. PubMed ID: 24166495
[TBL] [Abstract][Full Text] [Related]
5. Phase transition and remodeling complex assembly are important for SS18-SSX oncogenic activity in synovial sarcomas.
Cheng Y; Shen Z; Gao Y; Chen F; Xu H; Mo Q; Chu X; Peng CL; McKenzie TT; Palacios BE; Hu J; Zhou H; Long J
Nat Commun; 2022 May; 13(1):2724. PubMed ID: 35585082
[TBL] [Abstract][Full Text] [Related]
6. Histone deacetylase inhibitors reverse SS18-SSX-mediated polycomb silencing of the tumor suppressor early growth response 1 in synovial sarcoma.
Lubieniecka JM; de Bruijn DR; Su L; van Dijk AH; Subramanian S; van de Rijn M; Poulin N; van Kessel AG; Nielsen TO
Cancer Res; 2008 Jun; 68(11):4303-10. PubMed ID: 18519690
[TBL] [Abstract][Full Text] [Related]
7. Synovial sarcoma: when epigenetic changes dictate tumour development.
Riggi N; Cironi L; Stamenkovic I
Swiss Med Wkly; 2018 Nov; 148():w14667. PubMed ID: 30506527
[TBL] [Abstract][Full Text] [Related]
8. Truncated SSX protein suppresses synovial sarcoma cell proliferation by inhibiting the localization of SS18-SSX fusion protein.
Yoneda Y; Ito S; Kunisada T; Morimoto Y; Kanzaki H; Yoshida A; Shimizu K; Ozaki T; Ouchida M
PLoS One; 2013; 8(10):e77564. PubMed ID: 24130893
[TBL] [Abstract][Full Text] [Related]
9. The SS18-SSX Fusion Oncoprotein Hijacks BAF Complex Targeting and Function to Drive Synovial Sarcoma.
McBride MJ; Pulice JL; Beird HC; Ingram DR; D'Avino AR; Shern JF; Charville GW; Hornick JL; Nakayama RT; Garcia-Rivera EM; Araujo DM; Wang WL; Tsai JW; Yeagley M; Wagner AJ; Futreal PA; Khan J; Lazar AJ; Kadoch C
Cancer Cell; 2018 Jun; 33(6):1128-1141.e7. PubMed ID: 29861296
[TBL] [Abstract][Full Text] [Related]
10. Expanding the Use of an SS18-SSX Antibody for Molecular Assays in Synovial Sarcoma.
Raquib AR; Hofvander J; Ta M; Nielsen TO
Appl Immunohistochem Mol Morphol; 2022 Sep; 30(8):531-539. PubMed ID: 35880992
[TBL] [Abstract][Full Text] [Related]
11. The synovial-sarcoma-associated SS18-SSX2 fusion protein induces epigenetic gene (de)regulation.
de Bruijn DR; Allander SV; van Dijk AH; Willemse MP; Thijssen J; van Groningen JJ; Meltzer PS; van Kessel AG
Cancer Res; 2006 Oct; 66(19):9474-82. PubMed ID: 17018603
[TBL] [Abstract][Full Text] [Related]
12. Utility of Immunohistochemistry With Antibodies to SS18-SSX Chimeric Proteins and C-Terminus of SSX Protein for Synovial Sarcoma Differential Diagnosis.
Lasota J; Chłopek M; Kaczorowski M; Natálie K; Ryś J; Kopczyński J; Sulaieva O; Michal M; Kruczak A; Harazin-Lechowska A; Szczepaniak M; Koshyk O; Hałoń A; Czapiewski P; Abdullaev Z; Kowalik A; Aldape KD; Michal M; Miettinen M
Am J Surg Pathol; 2024 Jan; 48(1):97-105. PubMed ID: 37899499
[TBL] [Abstract][Full Text] [Related]
13. SS18-SSX-Dependent YAP/TAZ Signaling in Synovial Sarcoma.
Isfort I; Cyra M; Elges S; Kailayangiri S; Altvater B; Rossig C; Steinestel K; Grünewald I; Huss S; Eßeling E; Mikesch JH; Hafner S; Simmet T; Wozniak A; Schöffski P; Larsson O; Wardelmann E; Trautmann M; Hartmann W
Clin Cancer Res; 2019 Jun; 25(12):3718-3731. PubMed ID: 30814111
[TBL] [Abstract][Full Text] [Related]
14. Interdependence of SS18-SSX-driven YAP1 and β-Catenin Activation in Synovial Sarcoma.
Isfort I; Berthold R; Heinst L; Wardelmann E; Larsson O; Trautmann M; Hartmann W
Mol Cancer Res; 2023 Jun; 21(6):535-547. PubMed ID: 36920288
[TBL] [Abstract][Full Text] [Related]
15. The C terminus of the synovial sarcoma-associated SSX proteins interacts with the LIM homeobox protein LHX4.
de Bruijn DR; van Dijk AH; Willemse MP; van Kessel AG
Oncogene; 2008 Jan; 27(5):653-62. PubMed ID: 17667940
[TBL] [Abstract][Full Text] [Related]
16. A Novel SS18-SSX Fusion-specific Antibody for the Diagnosis of Synovial Sarcoma.
Baranov E; McBride MJ; Bellizzi AM; Ligon AH; Fletcher CDM; Kadoch C; Hornick JL
Am J Surg Pathol; 2020 Jul; 44(7):922-933. PubMed ID: 32141887
[TBL] [Abstract][Full Text] [Related]
17. Correlating SS18-SSX immunohistochemistry (IHC) with SS18 fluorescent in situ hybridization (FISH) in synovial sarcomas: a study of 36 cases.
Tay TKY; Sukma NB; Lim TH; Kuick CH; Goh JY; Chang KTE
Virchows Arch; 2021 Oct; 479(4):785-793. PubMed ID: 34091760
[TBL] [Abstract][Full Text] [Related]
18. A Role for SMARCB1 in Synovial Sarcomagenesis Reveals That SS18-SSX Induces Canonical BAF Destruction.
Li J; Mulvihill TS; Li L; Barrott JJ; Nelson ML; Wagner L; Lock IC; Pozner A; Lambert SL; Ozenberger BB; Ward MB; Grossmann AH; Liu T; Banito A; Cairns BR; Jones KB
Cancer Discov; 2021 Oct; 11(10):2620-2637. PubMed ID: 34078620
[TBL] [Abstract][Full Text] [Related]
19. Targeted degradation of BRD9 reverses oncogenic gene expression in synovial sarcoma.
Brien GL; Remillard D; Shi J; Hemming ML; Chabon J; Wynne K; Dillon ET; Cagney G; Van Mierlo G; Baltissen MP; Vermeulen M; Qi J; Fröhling S; Gray NS; Bradner JE; Vakoc CR; Armstrong SA
Elife; 2018 Nov; 7():. PubMed ID: 30431433
[TBL] [Abstract][Full Text] [Related]
20. When used together SS18-SSX fusion-specific and SSX C-terminus immunohistochemistry are highly specific and sensitive for the diagnosis of synovial sarcoma and can replace FISH or molecular testing in most cases.
Zaborowski M; Vargas AC; Pulvers J; Clarkson A; de Guzman D; Sioson L; Maclean F; Chou A; Gill AJ
Histopathology; 2020 Oct; 77(4):588-600. PubMed ID: 32559341
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]